Gene mapping predicts cancer variants with 100% accuracy


Researchers at the Francis Crick Institute have mapped all the possible outcomes of changes to a tumour-suppressing gene called VHL.

The VHL map could help clinicians work out which patients are at risk of developing kidney cancer or might respond to certain drugs.

It is the first step in a huge research endeavour to unpick the outcomes of tens of thousands of genetic variations in genes associated with cancer.

Both acquired and inherited variants in the VHL gene can increase the risk of kidney cancer. But many people are diagnosed with ‘variants of unknown significance’ in VHL and don’t know what this means for their cancer risk.

Saturation genome editing

Researchers at the Crick used a new method called saturation genome editing to track the function of over 2,000 different VHL variants in human cells over time.

They measured how many cells survived with each VHL variant, which was then given a ‘function score’: the lower the score, the more harmful the variant.

Most of the VHL variants analysed did not impact the survival of the cells, suggesting that people with these variants may not have a significantly higher risk. However, other variants were shown to be faulty for the first time, meaning patients with these variants may now be offered regular screening to reduce their cancer risk.

The most harmful variants caused the cells to die. The team found that the faulty VHL gene increased the activity of another gene called HIF. This gene is needed to help cells survive in low oxygen, but too much HIF protein can cause tumours.

Removing HIF from cells with these VHL mutations kept the cells alive, showing that the negative effects of VHL are dependent on HIF.

Belzutifan, a drug that inhibits the HIF protein, only works for people with mutations impacting the amount of HIF present in cells. The scoring system developed by the Crick team could identify people with VHL mutations who would benefit from belzutifan treatment.

Finally, the researchers compared their scoring system with publicly available databases on kidney cancer, finding that their method could predict cancer-causing variants previously identified in the clinic with 100% accuracy.

Predicting kidney cancer risk

Greg Findlay, Group Leader of the Genome Function Laboratory at the Crick, said: “Lots of people are told they have a ‘variant of unknown significance’ in the VHL gene and they’re in the dark about what that means for their cancer risk. Our variant function score could be a clinically useful test to categorise patients. In fact, we show that patients with the lowest scoring VHL variants tend to get kidney cancer at the highest rate. We are now working to apply this method to more genes to bring this level of diagnostic precision to more people.”

The lab is now working with the Cancer Dynamics Laboratory at the Crick to track how well the function score can predict tumour growth and response to treatment in patients with VHL mutations.

They are also working with the Wellcome Sanger Institute and The Institute of Cancer Research, London to map all variant effects across 15 other cancer risk genes.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free